newsfilter
← Latest News
GlobeNewswire·

NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results

LNCB74 (B7-H4 ADC) GLP tox studies completed and targeting an IND application by year-endNC410 combo with pembrolizumab ovarian cohort enrollment completedCash of approximately $86.4 million expected to fund operations